



SUDARSHAN PHARMA INDUSTRIES LTD

Head Office : 301, Aura Biplax, Premium Retail, Premises, 7, S.V. Road, Borivali (West), Mumbai - 400092.

E-mail : compliance@sudarshanpharma.com, **Website :** www.sudarshanpharma.com

Board Line : +91-22-42221111 / 43331111/42221116 (100 line) **CIN:** L51496MH2008PLC184997

SPIL/CS/SE/2025-2026/47

Date: 14th August 2025

To,

The Listing Department

BSE Limited

Phiroze Jeejeebhoy Towers,

Dalal Street, Mumbai – 400 001

BSE Scrip Code: 543828

BSE Trading Symbol: SUDARSHAN

ISIN: INE00TV01023

Sub: **Intimation for approval for acquiring capital assets**

Ref: **Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015**

Dear Sir / Madam,

Pursuant to Regulation 30 of SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations'), this is to inform you that the Board of Directors of the Company have at their meeting held on 14th August, 2025 approved to acquire land, building and plant & machinery, total admeasuring area 1,563.15 Square meters located at Plot nos. D-22, IDA-Medchal, Medchal Mandal, Malkajigiri District, Telangana, PIN - 501401 for a total sale consideration of Rs.25.50 Crores from Srigen Lifesciences Private Limited.

The details as required under the SEBI Listing Regulations read with SEBI Circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13th July 2023 are given in Annexure A.

Request you to take the same on your record.

Thanks & Regards,

Yours faithfully,

For, **Sudarshan Pharma Industries Limited**

Hemal Mehta

Chairman & Managing Director



Encl: As above



SUDARSHAN PHARMA INDUSTRIES LTD

Head Office : 301, Aura Biplax, Premium Retail, Premises, 7, S.V. Road, Borivali (West), Mumbai - 400092.

E-mail : compliance@sudarshanpharma.com, **Website :** www.sudarshanpharma.com

Board Line : +91-22-42221111 / 43331111/42221116 (100 line) **CIN:** L51496MH2008PLC184997

Annexure-A

Details required under Regulation 30 of the SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 read with SEBI Circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13th July 2023 are given below:

| Sl. No. | Details to be Provided | Information |
|---------|--|--|
| 1 | Name of the target entity, details in brief such as size, etc. | <p>The Company shall acquire Land, building and plant & machinery (Capital Assets), total admeasuring area 1563.15 Square meters located at Plot nos. D-22, IDA-Medchal, Medchal Mandal, Malkajigiri District, Telangana, PIN - 501401 for a total sale consideration of Rs.25.50 Crores from Srigen Lifesciences Private Limited.</p> <p>It has developed 50 potential API key starting materials having viable commercial technology. Few key starting materials were held as Patent rights by Srigen Lifesciences Private Limited and are currently being manufactured on commercial scale with proper regulatory documentation support. The Plant has 80 Kilolitres reactor capacity in its manufacturing facility.</p> |
| 2 | Whether the acquisition would fall within related party transactions and whether the promoter / promoter group / group companies have any interest in the entity being acquired? If yes, nature of the interest and details thereof and whether the same is done at 'arm's length' | <p>No.</p> <p>The acquisition of the Capital Assets would not fall within the related party transactions.</p> |
| 3 | Industry to which the entity being acquired belongs. | <p>The Capital Assets proposed to be acquired are utilized for manufacturing of pharmaceuticals and chemicals products such as Ropivacaine, Bupivacaine, Probenecid (Probalan), Sitagliptin, Apixaban, Rivaroxaban, etc.</p> |
| 4 | Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity) | <p>The acquisition of the Capital Assets will enable the Company to enlarge its production capabilities.</p> |





SUDARSHAN PHARMA INDUSTRIES LTD

Head Office : 301, Aura Biplax, Premium Retail, Premises, 7, S.V. Road, Borivali (West), Mumbai - 400092.

E-mail : compliance@sudarshanpharma.com, **Website :** www.sudarshanpharma.com

Board Line : +91-22-42221111 / 43331111/42221116 (100 line) **CIN:** L51496MH2008PLC184997

| | | |
|----|--|---|
| 5 | Brief details of governmental or any regulatory approvals required for the acquisition | As per the information available with us and explanation and statements given by the directors and / or management, the seller company will be doing the compliances as may be applicable under the provisions of the Companies act, 2013 read with rules and regulations made thereunder. |
| 6 | Indicative time period for completion of the acquisition | 31 st December, 2025 |
| 7 | Nature of Consideration whether Cash consideration or share swap and details of the same | Consideration for acquiring the Capital assets to be done in cash. |
| 8 | Cost of acquisition or the price at which the shares are acquired. | Rs.25,50,00,000/- only (Rupees Twenty Five Crores And Fifty Lakhs only). |
| 9 | Percentage of shareholding control acquired and / or number of shares acquired | Not Applicable |
| 10 | Brief background about the entity acquired in terms of products / line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief) | Brief background: It has developed 50 potential API key starting materials having viable commercial technology. Few key starting materials were held as Patent rights by Sripen Lifesciences Private Limited and are currently being manufactured on commercial scale with proper regulatory documentation support. The Plant has 80 Kilolitres reactor capacity in its manufacturing facility. |

For, Sudarshan Pharma Industries Limited

Hemal Mehta
Chairman & Managing Director

